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Objective: Explore	 trauma,	 stress,	 and	other	predictive	 factors	 for	 treatment	out-
come	in	conversion	disorder/functional	neurological	disorder	(CD/FND).
Methods: Prospective observational design. Clinical cohort study among consecu-
tive	 outpatients	 with	 DSM-IV	 CD/FND	 in	 a	 specialized	 mental	 health	 institution	
for	somatic	symptom	disorders	and	related	disorders	(SSRD),	presented	between	1	
February	2010	and	31	December	2017.	Patient	files	were	assessed	for	early	child-
hood	 trauma,	 childhood	 sexual	 abuse,	 current	 stress,	 and	 other	 predictive	 fac-
tors.	Patient-related	 routine	outcome	monitoring	 (PROM)	data	were	evaluated	 for	
treatment	 outcome	 at	 physical	 (Patient	 Health	 Questionnaire	 [PHQ15],	 Physical	
Symptoms	Questionnaire	[PSQ])	level	as	primary	outcome,	and	depression	(Patient	
Health	Questionnaire	[PHQ9]),	anxiety	(General	Anxiety	Disorder	[GAD7]),	general	









Conclusion: Childhood sexual abuse is significantly associated with poor treatment 
outcome	 in	 CD/FND.	 Randomized	 clinical	 trials	 evaluating	 treatment	 models	 ad-
dressing	childhood	sexual	abuse	in	CD	are	needed.
K E Y W O R D S
adverse	childhood	experiences,	childhood	sexual	abuse,	conversion	disorder,	functional	
neurological	disorder,	predictive	factors,	treatment	outcome
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1  | INTRODUC TION
1.1 | Background
Conversion	 disorder	 (CD)	 (Association	 AP,	 2013)	 or	 functional	
neurological	 disorder	 (FND)	 (Stone,	 Hallett,	 Carson,	 Bergen,	 &	
Shakir,	 2014)	 involves	 symptoms	 or	 deficits	 affecting	 voluntary	
motor	 or	 sensory	 function	 that	 suggests	 a	 neurologic	 condition,	
but lack a neurologic explanation after appropriate neurological 




in	 the	 2nd–4th	 decade	 and	 generally	 takes	 a	 protracted	 course	
with	high	limitations	in	general,	social	and	work	functioning	in	ad-
dition	to	high	medical	healthcare	utilization	(Merkler	et	al.,	2016).	
Family	 members	 also	 feel	 a	 burden	 (Griffith,	 Polles,	 &	 Griffith,	
1998)	 as	 patients	 with	 CD/FND	 often	 need	 long-time	 intensive	
help,	can	become	dependent	on	a	wheelchair,	and	may	need	ad-
aptations	 of	 their	 house	 and	 living	 arrangements.	 As	 treatment	




Stone	 &	 Vermeulen,	 2016;	 Sveinson,	 Stafánsson,	 &	 Hjaltason,	




Fine,	&	 Lang,	 2001).	 Thus,	 the	 individual	 and	 societal	 burden	of	
CD/FND	is	high	(Mace	&	Trimble,	1996).
The	work	on	unraveling	the	pathogenesis	of	CD/FND,	and	the	
role of recent and early stress as well as psychological and biolog-
ical	 vulnerabilities,	 is	 ongoing,	 as	 is	 indicated	 in	 a	 recent	 review	
(Keynejad,	Kanaan,	Pariante,	Reuber,	&	Nicholson,	2018).	Cross-
sectional	studies	exploring	cortisol	and	the	stress	response	in	CD/
FND	 found	 conflicting	 results.	 Apazoglou	 found	 a	 baseline	HPA	





Toledo,	 and	Hallett	 (2015)	 found	 that	 current	 stress	 levels	were	
not altered in patients with functional movement disorders and 







lar	 volume	was	 identified	 in	 an	MRI	 study	 in	 patients	with	 FND	
and	 childhood	 adversity	 (Perez	 et	 al.,	 2017).	 Childhood	 physical	
or	sexual	abuse	has	been	found	in	44%	of	patients	with	CD/FND	
(Roelofs,	Spinhoven,	Sandijck,	Moene,	&	Hoogduin,	2005)	and	 is	












a	 poor	 quality	 of	 life	 (Group	 S,	 2007;	 Martlew	 &	Marson,	 2014;	
Régny	&	Cathébras,	2016).	An	observational	study	in	the	neurolog-
ical setting found that psychiatric comorbidity and an inability to 




diagnosis and comorbid personality disorder predicted a negative 
outcome	(Gelauff,	Stone,	Edwards,	&	Carson,	2014;	Halligan,	Bass,	
&	Marshall,	2001).	Depression	(38%–50%),	anxiety	disorders	(35%),	






• Childhood sexual abuse is significantly associated with 
poor treatment outcome for physical symptoms in pa-
tients	with	conversion	disorder/FND.
•	 Randomized	clinical	 trials	evaluating	 treatment	models	
addressing childhood sexual abuse in conversion disor-
der/FND	are	needed.
Limitations
•	 The	 findings	of	 this	 study	are	generalizable	 to	 chronic	
complex	 conversion	 disorder/FND	 treated	 in	 the	 spe-
cialty	mental	health	setting,	not	to	incident	cases.
•	 Although	in	comparison	with	other	studies	in	this	field,	
the	 sample	 size	of	 this	 study	 can	be	 considered	 large,	
it is relatively small compared with other clinical epide-
miological cohort studies.





As	 a	 correlate	 of	 the	 evidence	 gap	 on	 pathogenesis,	 treatment	 of	
CD/FND	has	a	limited	evidence	base	(Ruddy	&	House,	2005).	Mental	
health	care	for	chronic	CD/FND	is	often	a	combination	of	outpatient	
and	 inpatient,	 multidisciplinary	 treatment	 (Demartini	 et	 al.,	 2014),	
of	 long	duration	and	with	 limited	results	 (Carson	et	al.,	2012;	Krull,	
2014).	 Although	 there	 is	 some	 evidence	 for	 cognitive	 behavioral	
therapy	 (Dallocchio,	 Bombieri,	 Arnó,	 &	 Erro,	 2016),	 physiotherapy	
(Nielsen,	 Stone,	 &	 Edwards,	 2013),	 transcranial	 magnetic	 stimula-
tion	(Garcin	et	al.,	2013;	Parin	&	Chastan,	2014;	Schönfeldt-Lecuona,	
Connemann,	 Spitzer,	 &	 Herwig,	 2003),	 and	 hypnosis	 (Moene,	
Spinhoven,	Hoogduin,	&	Dyck,	2002;	Moene,	Spinhoven,	Hoogduin,	
&	Dyck,	2003),	there	is	little	reliable	evidence	to	support	the	use	of	
any	 treatment,	 including	 CBT	 (Martlew	&	Marson,	 2014;	 Ruddy	&	
House,	2005).	These	knowledge	gaps	warrant	an	exploration	of	the	





1.	 Describe	 demographic	 and	 clinical	 characteristics	 of	 patients	
presenting	 themselves	 with	 CD/FND	 in	 a	 clinical	 centre	 of	
excellence for somatic symptom disorders and related disorders 
(SSRD)	 in	 the	 specialty	 mental	 health	 setting.
2. Explore the association between predictive factors and treatment 
outcome in terms of physical symptoms as the primary outcome.
3. Explore the same association with secondary outcomes; depres-
sion,	anxiety,	general	functioning,	and	pain.
3  | MATERIAL S AND METHODS
3.1 | Design










after neurological assessment and without clear evidence of an 
underlying	somatic	condition	explaining	their	symptoms,	were	eli-
gible.	In	each	case,	CD/FND	was	established	by	psychiatric	exami-
nation	 (PSE),	 taking	 all	 information	 from	 the	 intake	 into	 account	
and	according	to	DSM-IV	criteria	(Association	AP,	2001)	or	DSM-5	
criteria	 (Association	AP,	2013),	and	 if	needed,	 including	MINI	 in-
terview.. Eligible patients were identified in the data warehouse 
of	 the	 specialized	mental	 health	 institution	 (SMHI).	 Patient	 files	






tal	 disorders,	 early	 childhood	 trauma	 and	 childhood	 sexual	 abuse,	
recent	 life	 events,	 duration	 of	 symptoms	 and	 of	 earlier	 treatment	
before	referral	to	the	clinic,	psychosocial	factors,	and	family	history	
as possible factors affecting treatment outcome.
3.5 | Data sources
Patient files were assessed based on a checklist of potential pre-
dictive	 factors.	 Data	 were	 taken	 from	 the	 files	 according	 to	 a	
checklist	 that	 was	 put	 together	 beforehand,	 based	 on	 a	 review	
of	the	literature	for	possibly	relevant	predictive	factors.	A	search	
was	 performed	 in	 PubMed	 with	 the	 MESH	 terms	 ‘Conversion	






The	 standard	 intake	 procedure	 at	 the	CLGG	 consists	 of	 ques-
tionnaire assessment during intake (referred to as baseline measure-
ment),	 medical	 history	 assessment,	 physical	 assessment	 including	
neurological	 examination,	 psychiatric	 evaluation,	 and	 psychodiag-
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TA B L E  1  Data	sources	and	measurements
Factors Classification Based on






Type of conversion 1. With sensory symptoms







Patient file: intake letter
Time between development of 







Time period until treatment in 
CLGG
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Factors Classification Based on
Family composition 1.	Single	without	children
2.	Single	with	children
3. With a partner without children
4.	With	a	partner	with	children




2. Moderate (only a single family member or a 
single	friend)
3.	Bad	(no	friends/family)
























shortly before the onset 
















designed for administration to people aged 18 years 
and older. Questions cover family dysfunction; 
physical,	sexual,	and	emotional	abuse	and	neglect	
by parents or caregivers; peer violence; witnessing 
community	violence,	and	exposure	to	collective	
violence.	ACE-IQ	is	currently	being	validated	through	
trial implementation as part of broader health 
surveys (http://www.who.int/viole nce_injury_preve 























TA B L E  1   (Continued)
(Continues)
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3.6 | Data sources/measurements
The variables used and the data sources are shown in the table 
below. Patient files were checked for the respective measurements. 
‘Insert’	Table	1	(Supplementary	material).
3.7 | Treatment
Treatment	 at	 CLGG	 was	 standardized	 and	 multimodal,	 following	
the multidisciplinary guideline for medically unexplained symptoms 
and	 somatic	 symptom	 disorders,	 with	 a	 focus	 on	 CD/FND	 (Van	
der	 Feltz-Cornelis,	Hoedeman,	 Keuter,	 &	 Swinkels,	 2012;	 Van	 der	
Feltz-Cornelis,	Swinkels,	Blankenstein,	Hoedeman,	&	Keuter,	2011).	
Treatment contained two parallel tracks:
On	the	one	hand,	exploring	the	somatic	history	and	diagnostic	
assessments	carried	out	 leading	to	the	diagnosis	of	CD/FND;	pro-
viding explanation of the physical symptoms and psychoeducation 
to the patient; providing treatment of any relevant identified somatic 








ing	 treatment	 (PST)	 (Malouff,	 Thorsteinsson,	 &	 Schutte,	 2007;	
Wilkinson	 &	 Mynors-Wallis,	 1994)	 provided	 by	 trained	 psy-
chologists,	 in	 combination	 with	 pharmacotherapy	 provided	 by	
a physician or psychiatrist. The psychotherapeutic treatments 
were	 provided	 sequentially	 and	were	 tailored	 to	 the	 needs	 and	
treatment expectations of the patients. Every 3 months during 
treatment,	 both	 the	 psychotherapeutic	 and	 pharmacotherapeu-






Bias was avoided by checking all patient files systematically for the 
predictive factors according to the checklist which was derived from 
a	review	of	the	 literature.	 In	a	pilot,	 the	data	feeding	the	checklist	
were	extracted	in	duplicate	(RH	and	JvE),	and	the	feasibility	of	this	
approach	was	indicated	after	assessment	in	14	files.	The	data	extrac-




sible to establish an association between treatment outcome and 
6	 predictive	 factors	 with	 sufficient	 power	 (Nunnaly	 &	 Bernstein,	
1994).
3.10 | Quantitative variables
Primary outcomes were physical symptoms measured by the 
Patient	Health	Questionnaire	(PHQ15)	and	the	Physical	Symptoms	
Questionnaire	 (PSQ)	 (Van	 Hemert,	 2003)	 at	 end	 of	 treatment.	
Secondary	 outcomes	 were	 anxiety,	 depression,	 pain,	 and	 general	
functioning at end of treatment measured by the Patient Health 





Covariates	 were	 type	 of	 CD/FND,	 childhood	 adverse	 experi-
ences	 (ACE)	 including	 childhood	 sexual	 abuse,	 life	 events,	 comor-





and entered into a model together.
















TA B L E  1   (Continued)




were performed to explore associations of predictors with treatment 
outcome	in	CD/FND.	Analyses	were	performed	using	listwise	dele-
tion	to	address	cases	of	missing	data.	For	the	secondary	outcomes,	
hierarchical multiple regression analyses were performed.
3.12 | Sensitivity analyses
One sensitivity analysis explored the associations while control-
ling	for	baseline	scores	of	secondary	outcomes.	Another	sensitivity	
analysis explored if patients following up the intake with treatment 
at	the	CLGG	differed	significantly	from	patients	who	did	not	proceed	












Mean	 age	was	 43	 years.	 About	 79.5%	of	 the	 sample	were	 fe-
male,	and	59.4%	were	married	or	living	together.	The	majority	of	the	
patients had a history of multiple diagnostic procedures by neurolo-
gists and other medical specialists and started psychiatric treatment 
at	 least	12	months	after	 the	onset	of	 the	CD/FND	symptoms.	On	
average,	 5	 years	 elapsed	 before	 presentation	 at	 CLGG.	 The	most	
common	 CD/FND	 was	 with	 motor	 symptoms	 (39.1%).	 CD/FND	
with	mixed	 symptoms	came	second	 (26.6%).	One	patient	 suffered	
from	foreign	accent	syndrome,	which,	if	of	functional	nature,	can	be	
considered	a	conversion	disorder	 (Keulen	et	al.,	2016).	About	66%	


















secondary outcomes at baseline and end of treatment in patients 
with	CD/FND.
Paired samples t tests show that physical symptom scores 
(PHQ15),	 depressive	 symptoms	 (PHQ9),	 and	 anxiety	 symptoms	
(GAD7)	decreased	significantly	 from	baseline	 to	end	of	 treatment.	
The	 decrease	 in	 PSQ,	 another	 questionnaire	 exploring	 physical	
outcomes,	and	general	 functioning	 (SF36)	approached	significance	
F I G U R E  1   Flowchart participants
Patients with 
confirmed CD/FND 
following treatment  
at CLGG and with at 
least one follow up
PROM (N = 43)
Patients diagnosed 
with CD/FND after 
intake assessment at 
CLGG (N = 73)
Exclusion (N = 9)
No informed consent
Patients with CD/FND 
following treatment at 
CLGG (N = 44)
Patients with CD/FND
not entering 
treatment phase at 
CLGG (N=20)
Patients with CD/FND 
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n % n %
Sex   Type of Conversion disorder   
Male 13 20.3 With sensoric symptoms 5 7.8
Female 51 79.5 With motor symptoms 25 39.1
   With	nonepileptic	seizures 9 14.1
Age M	=	43.14 SD	=	11.58 With mixed symptoms 17 26.6
   Other 6 9.4
Relationship status      
Single 21 32.8 Time between symptom onset to start of treatment   
Cohabiting 14 21.9 <3 months 5 7.8
Married 24 37.5 3–6	months 6 9.4
Long-distance 5 7.8 6–12	months 10 15.6
   >12	months 42 65.6
Family status      
Single	no	children 20 31.3 Onset   
Single	with	children 7 10.9 Acute 27 42.2
Partner no children 10 15.6 Gradually 37 57.8
Partner with children 27 42.2    
   Time from symptom onset to start of treatment in 
CCLG	(months)
M	=	61.11 SD	=	70.49
Social	network      
Good 27 42.2 Comorbid disorders   
Mediocre 31 48.4 Personality disorder 26 40.6
Bad 5 7.8 Anxiety	disorder 31 48.4
   Depressive	disorder 27 42.2
Education   Psychotic disorder 2 3.1
Very	low 8 12.5 Developmental	disorder 11 17.2
Low 20 31.3 Addiction 3 4.7
Middle 23 35.9 Thyroid disorder 7 10.9
High 9 14.1 Adrenal	disorder 0 0
Very	high 1 1.6 Other somatic disorder 17 26.6
   Stroke 7 10.9
Work status   Epilepsy 2 3.1
Working 13 20.3 Other neurological condition 6 9.4
Sickness	benefits 15 23.4 Other somatic condition 40 62.5
Unemployment	benefits 4 6.3    
Social	assistance	benefit 7 10.9 Use	of	Medication   
Disabled 18 28.1 Antidepressants 29 45.3
Retired 2 3.1 Benzodiazepines 17 26.6
   Antipsychotics 5 7.8
Trauma/Stress   Pain medication 24 37.5
Childhood trauma 45 70.3 Opiates 12 18.8
Recent life event 41 64.1    
Sexual	abuse	in	
childhood
17 26.6 Pain (n	=	62)   
(Continues)
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(p =	 .052	and	p =	 .056,	 respectively).	Pain	 symptoms	 (BPI)	did	not	
show a significant change.
In	Table	4,	differences	in	outcomes	are	shown	between	patients	
who experienced childhood sexual abuse and those who did not.
Independent	 samples	 t tests show that at the end of treat-
ment those who suffered sexual abuse in childhood reported sig-
nificantly	 higher	 scores	 on	 the	 PSQ	 (physical	 symptoms)	 and	 on	
the	GAD7	(anxiety)	than	those	who	did	not	report	sexual	abuse	in	
childhood.
4.2.1 | Predictors of treatment outcome
Significant	associations	between	predictors	and	primary	outcomes	and	
between predictors and secondary outcomes are shown in Table 5.
With	 respect	 to	 the	 primary	 outcomes,	 linear	 regression	
analyses indicated sexual abuse in childhood (F[1,	 28]	 =	16.435,	
β	 =	0.608,	p <	 .001)	was	 the	only	 significant	 predictor	 of	 physi-
cal	symptoms	as	measured	by	the	PSQ	at	follow-up.	The	presence	
of	ACE	 and	 having	 an	ACE	 score	 of	 4	 or	more	were	 not	 signifi-
cantly	 associated	with	 treatment	 outcome,	 and	 neither	 was	 the	
presence	of	current	stress.	 In	 terms	of	secondary	outcomes,	 lin-
ear regression analyses indicated that the presence of a comor-
bid depressive disorder at intake was significantly associated with 
higher scores on the PHQ9 (F[1,	39]	=	11.526,	β	=	0.478,	p =	.002)	







Hierarchical multiple regression analyses showed that when baseline 
scores	were	controlled	for,	comorbid	depressive	disorder	remained	
a significant predictor of both the PHQ9 (β	 =	 0.324,	ΔR2	 =	 .090,	
p =	.025)	and	GAD7	(β	=	0.328,	ΔR2	=	.099,	p =	.049)	scores	at	follow-
up	within	 each	 respective	model.	 Also,	 when	 baseline	 BPI	 scores	
were	 entered	 into	 the	 model,	 the	 presence	 of	 a	 comorbid	 devel-
opmental	disorder	was	not	a	 significant	predictor	of	BPI	 scores	at	
follow-up	(β	=	−0.263,	ΔR2	=	.037,	p =	.106).
Another	 sensitivity	 analysis	 explored	 if	 patients	 following	 up	
the	 intake	with	 treatment	 at	 the	CLGG	differed	 significantly	 from	
patients who did not proceed with treatment in terms of baseline 





5.1 | Summary of principal findings














n % n %
Death	of	a	loved	one 3 4.7 BPI	>	0 57 91.9
Adverse	childhood	events	
(ACE)	(n	=	30)
  BPI	≥	3 54 87.1
ACE	>	0 24 80 Mean	BPI	score M	=	5.09 SD	=	3.39
ACE	>	1 22 73.3    
ACE	≥	4 13 43.3    
Mean	ACE	scores M	=	4.10 SD	=	3.78    
Family history      
Family member with 
CD/FND
0 0    
Family member with 
other psychiatric 
disorder
24 37.5    
TA B L E  2   (Continued)








USA	 (Centers	 for	 Disease	 Control	 &	 Prevention,	 2016).	 This	 is	 also	
higher	than	the	77.2%	of	patients	reporting	at	least	one	ACE	in	a	study	










high levels of adverse childhood experiences.
Recent	 life	 events	 are	 highly	 prevalent	 as	 well;	 however,	 al-
though	 the	 burden	 of	 general	 ACE	 and	 recent	 stressful	 events	
in	this	study	 is	high,	they	are	not	associated	with	treatment	out-
comes. The primary and several secondary treatment outcomes 
improved significantly after treatment in the whole group and the 
only predictor significantly associated with worse physical treat-
ment	 outcome	was	 childhood	 sexual	 abuse.	 A	 separate	 analysis	
shows that not only worse physical outcomes but also higher anx-
iety levels at end of treatment in those who suffered sexual abuse 
in childhood.
Comorbid depressive disorder has a significant negative asso-




End of treatment 
(M [SD) t df p
PSQ	(n	=	30) 23.33	[21.54] 17.70	[22.23] 2.022 29 .052
PHQ15 (n	=	28) 12.25[5.30] 10.00 [5.31] 2.294 27 .030*
PHQ9(n	=	41) 13.63	[7.16] 10.88 [8.22] 2.355 40 .023*
GAD7(n	=	35) 10.51	[5.24] 6.97	[5.37] 3.545 24 .001**
SF36(n	=	26) 17.54	[3.84] 15.88 [3.36] 2.006 25 .056
BPI(n	=	38) 5.68 [2.60] 5.58 [2.51] 0.246 37 .807




*p < .05 (Mean scores [SD]).	
**p < .001. 
Bold indicates significant finding.
TA B L E  3   Paired samples t test 
indicating improvement in primary and 
secondary outcomes from baseline to 
end of treatment in group who received 
treatment (n	=	43)
Outcome
(M [SD])  
Childhood sexual abuse
t df pYes (n = 11) No (n = 32)
PSQ Baseline 35.36 [26.56] 22.34	[21.43] 1.635 41 .110
Follow-up 39.75	[33.08] 9.68 [9.00] 4.054 28 .000**
PHQ15 Baseline 13.00	[4.60] 14.25	[6.35] −0.599 41 .552
Follow-up 10.83 [5.31] 9.77	[5.42] 0.427 26 .673
PHQ9 Baseline 14.82	[7.15] 13.52	[7.08] 0.528 42 .601
Follow-up 14.78	[8.59] 9.78	[7.90] 1.646 39 .108
GAD7 Baseline 12.00 [6.18] 10.71	[5.25] 0.669 40 .507
Follow-up 10.33 [6.82] 6.15	[4.61] 2.086 34 .045*
SF36 Baseline 18.43	[3.78] 17.61	[3.96] 0.495 33 .624
Follow-up 16.20 [3.56] 15.21	[4.15] 0.496 27 .624
BPI Baseline 5.09 [3.39] 5.52	[2.43] −0.454 42 .652
Follow-up 6.30 [1.25] 5.32 [2.80] 1.060 36 .296
*p <	.05	(mean	scores,	SD).	
**p < .001. 
Bold indicates significant finding.
TA B L E  4   Independent	samples	t 
tests indicating differences in outcomes 
between patients who had encountered 
sexual abuse in childhood and those who 
had not within the group who received 
treatment (n	=	43)
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and	anxiety	symptoms.	This	might	be	interpreted,	as	that	CD/FND	
is harder to treat whether comorbid depressive or anxious disorder 
feed into catastrophic interpretations of the symptoms and the ex-
pected course.
Pain seems to be a physical symptom of particular importance 












prove significantly in case of comorbid developmental disorders 
such	as	adult	ADHD	or	autism	spectrum	disorder.	This	influence	
on treatment outcomes disappeared after correction for baseline 
pain	 levels,	 indicating	 that	 patients	with	 adult	ADHD	or	 autism	
spectrum	disorder	had	higher	pain	levels	at	intake,	and	benefitted	
from the treatment for pain outcomes. This patient group bene-
fitted	relatively	better	 from	the	treatment	 intervention,	at	 least	
for	 the	 pain	 component	 of	 their	 condition,	 than	 the	 group	 as	 a	
whole.
The sensitivity analysis comparing the patients that continued to 





higher levels of anxiety have a higher motivation for treatment and 
could also reflect levels of health anxiety related to the symptoms 
for which treatment was sought.
5.2 | Strengths and weaknesses of the study
A	strength	of	 this	 study	 is	 the	 longitudinal,	prognostic	design,	and	
the	exploration	of	predictors	of	treatment	outcome,	including	child-
hood	sexual	abuse	and	psychiatric	comorbidity,	which	is	a	first	in	the	
literature. This way we could establish for the first time that sexual 
abuse in childhood is associated with worse physical treatment out-
come; that comorbid depression has a negative impact on concomi-
tant	depressive	and	anxiety	symptoms	in	CD/FND;	and	that	patients	
with	comorbid	CD/FND,	pain,	and	comorbid	developmental	disorder	
benefit more from treatment. The fact that this study is conducted 
in a specialty mental health setting can also be seen as a strength 
of	 the	 study,	 as	 so	 far,	 studies	 have	been	performed	 in	 neurology	
clinics	that	in	general	see	first	presentations,	whereas	here	we	have	
the	opportunity	to	explore	a	cohort	with	chronic	CD/FND.	Another	
strength of the study is that we were able to perform sensitivity anal-
yses showing our findings to be robust and indicating possibly higher 
health	anxiety	levels	in	the	group	proceeding	to	treatment	at	CLGG.
Limitations	of	 the	 study	 are	 that	 due	 to	 the	 study	 setting	 and	






clinical epidemiological cohort studies.
5.3 | Implications
This study shows that treatment involving a parallel track combina-
tion	 of	 revisiting	 the	 somatic	 history,	 providing	 psychoeducation,	
and providing tailored psychotherapeutic and medical treatment 
in	 a	 shared	 decision	 model	 (SDM)	 (Van	 der	 Feltz-Cornelis	 et	 al.,	
2014)	 is	 associated	 with	 significant	 improvement	 of	 somatic	 and	
Predictor Outcome b SE b β t p R2
Primary outcomes        
Sexual	abuse	in	
childhood
PSQ 30.068 7.417 0.608 4.054 .001** .370
Secondary	
outcomes
       
Depressive	
disorder
PHQ9 7.755 2.284 0.478 3.395 .002* .228
Depressive	
disorder
GAD7 4.712 1.671 0.435 2.820 .008* .190
Developmental	
disorder
BPI −2.636 0.970 −0.412 −2.716 .010* .170
Note: b	=	unstandardized	beta,	SE b	=	standard	error	of	unstandardized	beta,	β	=	standardized	beta,	
R2	=	R-squared.
*p < .05. 
**p < .01. 
Bold indicates significant finding.
TA B L E  5  Linear	regression	analyses	
showing significant associations between 
predictors	and	primary	(PSQ)	and	
secondary outcomes
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psychological	 treatment	 outcomes.	 As	 this	 was	 an	 observational	
study,	 and	 in	 view	 of	 the	 lack	 of	 effective	 evidence-based	 treat-
ments	for	this	condition,	a	randomized	clinical	trial	exploring	treat-
ment effect of the described intervention is warranted.
The finding that childhood sexual abuse is associated with sig-
nificantly worse treatment outcome warrants the development and 





susceptibility of pain to improvement in patients with comorbid 
adult developmental disorders warrants development and evalua-
tion of medical and psychotherapeutic treatment models specifically 
targeting	pain	in	CD/FND	with	comorbid	adult	ADHD/autism	spec-
trum	disorder,	as	this	may	be	a	subgroup	of	patients	with	potential	
for more benefit of treatment.
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